Image: Investing News NetworkWhile Measles Cases Continue to Increase in The USA and Globally, NanoViricides is Getting Ready for Clinical Trials of Its Revolutionary Broad-spectrum Drug Candidate NV-387 as A Treatment for Measles
• NanoViricides, Inc. (NYSE American: NNVC) announced on August 31, 2026, that it is preparing for clinical trials of its broad-spectrum drug candidate, NV-387. • The drug utilizes host-mimetic nanomedicine technology designed to treat measles, a disease currently seeing a rise in cases both within the USA and globally. • This development is significant as it aims to provide a revolutionary antiviral treatment that viruses cannot easily escape, addressing a critical gap in measles management.
investingnews.com
![Todd Blanche Could Take Voter Roll Cases Before Supreme Court [Op-Ed] - 92 Q](/_next/image?url=https%3A%2F%2Fnewsone.com%2Fwp-content%2Fuploads%2Fsites%2F22%2F2026%2F08%2F1786990052911.jpg%3Fquality%3D80%26strip%3Dall%26w%3D1024%26crop%3D0%2C0%2C100%2C683px&w=1920&q=85)
